HealthMed Holdings Announces New Blood Test That Identifies Individuals Who Are At Risk Of A Heart Attack

HealthMed is Enabling Prevention of Heart Disease By Early Detection. (PRNewsFoto/HealthMed Holdings)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DOHA, Qatar and IRVINE, Calif., Feb. 13, 2014 /PRNewswire/ -- HealthMed Holdings, a company dedicated to the prevention of cardiovascular disease through innovative laboratory tests in conjunction with preventive strategies, announced today that it has completed validation on a novel blood test that aims to identify individuals who are at risk of a heart attack that might be missed by conventional tests. These individuals have no symptoms and frequently have normal standard blood cholesterol profiles, but are at significant risk of having a heart attack in the near term. The group is actively commercializing the test.

The new MAP Test (Myocardial Assessment Profile) covers pathways involved in unstable cardiac lesions due to inflammation. Inflammation is the most common cause of heart attacks (up to 75%).

HealthMed Holdings Managing Partner, Douglas S. Harrington, MD, said that the test will be offered globally with a focus on nations where there has been a steep rise in cardiac disease, obesity and diabetes.

"Increasing awareness that lifestyle choices significantly determine heart attack and stroke risk, and deficiencies in current diagnostic tools miss, many individuals who go on to have a heart attack or stroke determined a need for ways to identify these individuals so preventive measures can be taken. The health care authorities in many countries are taking a proactive approach to reversing these trends," said Dr. Harrington.

About the MAP Test™
The MAP Test measures compounds in the blood associated with vascular inflammation causing unstable cardiac lesions. Measurement of these compounds in a person's serum enables identification of patients at risk of a heart attack in the near term.  The MAP Test allows physicians to more effectively manage and treat their patients to the new ACC/AHA Cardiac guidelines – aiding in the reduction and prevention of cardiac events. Used in conjunction with other clinical information, the MAP Test's easy to understand results yield better compliance and behavioral changes by patients.

About HealthMed Holdings
HealthMed Holdings is dedicated to promoting preventive healthcare strategies through global alliances to deploy innovative diagnostic technologies in conjunction with lifestyle modification programs and medical compliance education.

Company Contacts:
Douglas S. Harrington, M.D.
Managing Partner, HealthMed Holdings
Al Jabor Group Building, C Ring Road, P.O. Box 36120
Doha Qatar (USA 949-547-3140)

Multimedia Assets associated with this release:
Logo: http://photos.prnewswire.com/prnh/20140213/LA65185LOGO

SOURCE HealthMed Holdings

reade more... Résuméabuiyad

ZIO ® service identifies arrhythmias significantly more than the traditional Holter Monitor, according to study published online in the American Journal of medicine

SAN FRANCISCO, 02 January 2014/PRNewswire /-iRhythm Technologies, a company of services of health information, today announced that a prospective study from the Scripps Translational Science Institute (STSI) has found that the use of the service of the company ZIO significantly increased detection of cardiac arrhythmias, compared to the use of the traditional Holter monitor. Findings, published and made publicly accessible online in the January issue of the American Journal of Medicine, underscore the role of the service ZIO, ZIO, patented algorithms patch and ZIO review, as the new standard for the ambulatory monitoring of patients with suspected arrhythmia.

"This is the first large prospective validation that this new technology passed the device invented by Norman Holter in 1949," said the lead author of the study, Dr. Eric Topol, a cardiologist who directs STSI and serves as the academic director of Scripps Health. "By tracking every beat of the heart up to two weeks, ZIO service proved to be significantly more sensitive than the Holter standard, it uses multiple threads and it is normally only used or tolerated during 24 hours.

"For" millions of people who presented each year with suspected arrhythmia, this could to be the new standard for the capture of the electric guilty heart rhythm disturbance, most commonly atrial fibrillation that carries a significant risk of race, he said.

The prospective study included 146 consecutive patients of Scripps Health who were referred for evaluation of cardiac arrhythmias and underwent an outpatient monitoring simultaneous ECG with ZIO patch, a patch on the chest, which continuously monitor the heartbeat records up to 14 days and a conventional 24-hour Holter, a portable machine with multiple cables that connect to the electrodes on the chest. Total wear of both devices, the service of ZIO time detected events of arrhythmia 57% more in comparison with the Holter monitor (96 against 61), mainly due to the prolonged monitoring. The doctors also reported that they reached a definitive diagnosis in 90% of cases using the ZIO service, compared with 64% with the Holter monitor. In addition, 81% of the patients reported that they preferred the ZIO patch versus the Holter monitor.

"The traditional options of monitoring heart are limited in their ability to capture the arrhythmias, which are rare and often do not have symptoms, and because they are difficult for patients to comply", said Kevin King, President and Chief Executive Officer of iRhythm. "These studies findings underscore that the ZIO service is setting a new standard for the diagnosis of arrhythmia, with a focus continuous monitoring proven, long-term which allows doctors to rule in and rule out arrhythmias before in the way of diagnosis and change the treatment of the patients."

Each year, millions of patients presenting with low common and non-specific symptoms such as palpitations, dizziness, and shortness of breath, which may or may not be caused by cardiac arrhythmias. Reports estimate that the three most common types of arrhythmia, atrial fibrillation (AF), bradycardia and ventricular tachycardia - affect approximately 8 million people in the United States each year. If it is not correctly, arrhythmias can lead to serious complications such as stroke. Effective management of cardiac arrhythmia is specific to the identified type of arrhythmia. Arrhythmias, however, are often difficult to diagnose using techniques of monitoring current, that they are limited in what you can record or it can be difficult for patients to use or tolerate.

About ZIO service
Service ZIO, ZIO, patented algorithms patch and ZIO report, is recognized more and more as the new standard for patients with suspected arrhythmia ambulatory cardiac monitoring. ZIO patch is a non-invasive, resistant to water, which is easy to use and discreet to wear, high compliance of the patient and a higher diagnostic yield. Proprietary algorithms analyze the data hit captured heart and provides a concise report to the patient's physician. Since its commercial launch in 2011, has been ZIO service with more than 200,000 patients in nearly 800 institutions throughout the country. ZIO is covered by most Medicare patients and main payers private throughout the country, representing more than 150 million of lives covered.

About iRhythm Technologies, Inc.
iRhythm is a company of services of health information that aims to be the world leader in information of cardiac arrhythmia management, a large and growing clinical need. Your solution of ship logo, ZIO service, offers an approach proven for continuous monitoring in the long term that allows early diagnosis in the clinical way to improve patient outcomes and reduce healthcare costs. For more information, visit www.irhythmtech.com.

Press contact:

Tracy Morris
650-380-4413
tracymorrispr@gmail.com

SOURCE iRhythm Technologies

RELATED LINKS
http://www.irhythmtech.com

reade more... Résuméabuiyad